In our exclusive interview, Dr Dietrich discussed key efficacy findings from the 18-month follow-up of the phase 2 VISION trial (NCT02864992), which evaluated the efficacy of tepotinib (Tepmetko) in patients with non–small cell lung cancer harboring MET exon 14 skipping mutations. Additionally, Dr Dietrich emphasized important safety considerations with tepotinib, particularly the management of on-target adverse effects (AEs) like edema. He also discussed strategies for addressing treatment-related AEs, such as hyperalbuminemia, hyponatremia, and kidney function abnormalities, and highlighted the importance of careful monitoring to make dose adjustments as necessary.